Plasmids expressing different domains of the hepatitis C virus (HCV) envelope E2 glycoprotein from a genotype 1a isolate were constructed to compare the immunogenic potential of E2 in nucleic acid-based immunizations. One plasmid, pCIE2t, expressed a C-terminally truncated form of E2, while others, pS2.SE2A to pS2.SE2E, encoded the adjacent 60-amino-acid (aa) sequences of E2 (inserts A to E) expressed as a fusion with the hepatitis B virus surface antigen. BALB/c mice were given injections of the plasmids intramuscularly (i.m.) or intraepidermally (i.e.) via a gene gun (biolistic introduction), and induced humoral immune responses were evaluated. The i.e. injections resulted in higher seroconversion rates and antibody titers, up to 100-fold, than did the i.m. injections (P ‫؍‬ 0.01 to 0.04). Three restricted immunogenic domains, E2A (aa 384 to 443), E2C (aa 504 to 555), and E2E (aa 609 to 674), that yielded antibody titers ranging from 1:59 to >1:43,700 could be identified. Subtype 1a-and 1b-derived E2 antigens and synthetic peptides were used in Western blot and enzyme-linked immunosorbent assay analyses, which revealed that the cross-reactivity of the plasmid-induced antibodies was linked both to the type of antigen expressed and to the injection mode. Induced anti-E2 antibodies could immunoprecipitate noncovalent E1E2 complexes believed to exist on the surface of HCV virions. This study allowed us to identify restricted immunogenic domains within E2 and demonstrated that different routes of injection of HCV E2 plasmids can result in quantitatively and qualitatively different humoral immune responses.
Hepatitis C virus (HCV) has been shown to be the major causative agent of non-A, non-B hepatitis. Its prevalence in the blood donor population has been estimated to range between 0.4 and 2.0% (4) . In more than 70% of cases, HCV causes a prolonged, persistent infection, which can eventually lead to cirrhosis and hepatocellular carcinoma (HCC) (41) . In France, HCV infections have become the prevalent cause of HCC, and it is estimated that more than 30,000 cases of HCC directly related to HCV infection will occur by the year 2010 (3). Community-acquired infection is still common and causes significant morbidity as well as important economic burdens (33) . In addition, the current lack of efficient antiviral treatment renders the development of a vaccine desirable.
Lines of evidence obtained from clinical and experimental studies in humans and chimpanzees suggest that the infected host is unable to mount an effective immune response capable of limiting the infection or preventing it after new challenges (11, 22, 39) . A certain degree of immunity is nonetheless mounted following primary infection. Prince et al. documented that episodes of hepatitis following a second challenge in the chimpanzee tend to be milder than primary infections (39) . Following primary infection, the induced humoral and cellular response, so far documented by the induction of specific CD8 ϩ cytotoxic T lymphocytes (CTL) and CD4 ϩ T-helper (Th) lymphocytes, is directed at almost all encoded viral antigens (for a review, see reference 27). At present, no correlation has been established between CTL activity (from blood-circulating as well as liver-infiltrating lymphocytes) directed at a specific antigen or specific determinant and the development or outcome of the disease. Recent studies suggest that enhanced CD4 ϩ proliferative responses, preferentially directed at the core and the NS3 protein, are associated with self-limited or asymptomatic infections (2, 12, 20, 29) . In addition, evidence suggestive of a potential neutralizing role of antibodies directed at the viral envelopes E1 and E2 has accumulated. Successful in vivo protection of chimpanzees has been achieved following immunization with recombinant E1 and E2 proteins (5) . In this model, a correlation was established between titers of induced anti-E2 antibodies and protection. In addition, a recently developed assay was used to show that sera from protected chimpanzees contained antibodies capable of neutralizing the binding of E2 to the presumed cell surface receptors (40) . Antibodies directed at the N-terminal region of E2, the socalled hypervariable region (HVR) (49) , have also been implicated in the control of infection (23, 43) . This region contains several linear B-cell epitopes as well as CTL epitopes (23, 26, 29, 30, 44, 50) , and specific antibodies directed at this region were reported to block viral attachment to susceptible cells (53) .
It is not an obvious decision to exploit the participation of immune responses directed at HCV envelope proteins for the development of a vaccine in view of accumulated data demon-strating that both antigenic domains, particularly E2, are prone to mutational changes and the appearance of immune escape mutants (19, 24, 46) . Nonetheless, the use of such antigens in a vaccine formulation should be evaluated, as neutralizing determinants do appear to exist, although they remain to be identified. In fact, E2-specific determinants have been very poorly described. In particular, identification of genotypeand/or subtype-conserved determinants has been limited in part because of difficulties in obtaining appropriate analytical tools. The study by Choo et al. (5) is the only one to report on immunizations with HCV E2-derived antigens. While the data are original and encouraging, the performance of the study was limited in particular with respect to analyzing the neutralizing potential and immune cross-reactivity of the induced antibodies.
The aim of our study was to explore, in the murine model, the immunogenic potential of HCV E2 protein when directly injected as naked plasmid DNA. More specifically, this study addresses issues related to the induction of anti-E2 humoral immune responses in terms of (i) evaluating the competence of DNA immunization for induction of high and stable anti-E2 antibody titers, (ii) identifying E2 subtype-variable or -conserved immunogenic regions, (iii) analyzing the capacity of E2-plasmid induced antibodies to recognize a mature form of the protein as a predictor of neutralization, and (iv) evaluating the influence of the injection mode by comparing intramuscular (i.m.) injections with gene gun-mediated introduction of DNA into the epidermis (intraepidermal [i.e.] injections) on the type of induced immune responses.
Plasmids and in vitro expression studies. Plasmids which expressed different forms and different domains of the HCV E2 protein were designed. One plasmid, pCIE2t, contained the near full-length E2 sequence (Fig. 1A) , while other plasmids, pS2.SE2A to pS2.SE2E, included predicted E2 antigenic domains that were expressed as fusion proteins with the hepatitis B surface antigen (HBsAg), resulting in HBV-HCV chimeric vectors (Fig. 1B) . These latter plasmids were derived because fusion proteins with the HBsAg have been shown, in previous studies, to be effective for the presentation of foreign epitopes (7, 32, (34) (35) (36) . All cloning techniques are those of to Sambrook et al. (42) . Briefly, the vector pCIE2t contains HCV E2 sequence from nucleotides (nt) 1341 to 2363 that was truncated from the hydrophobic C-terminal 216 nt and encompassed 132 nt from the C-terminal end of E1. The plasmid was derived by cloning the HCV sequence obtained by PCR amplification with a vector encompassing the full-length cDNA sequence of HCV-H into the NheI-EcoRI sites of the expression vector pCI (Promega, Madison, Wis.) (Fig. 1A) . The five adjacent, nonoverlapping fragments of HCV E2 (fragments E2A to E2E) were amplified by PCR from the same original vector and inserted into the EcoRI and XhoI sites of the pre-S portion of the pCMV-S2.S vector to create the HBV-HCV chimeric vectors pS2.SE2A to pS2.SE2E. The pCMV-S2.S vector expresses the HBV major (pre-S2 plus S) and middle (S) surface antigens. HCV inserts mapped to nt 1493 to 1672 (E2A), nt 1673 to 1852 (E2B), nt 1853 to 2011 (E2C), nt 2014 to 2164 (E2D), and nt 2168 to 2363 (E2E). Inserts E2A to E2E were selected on the basis of two criteria: (i) each fragment encompassed at least one predicted antigenic domain (Fig. 1C) , and (ii) amino acid bounderies were selected to minimize the presence of internal initiation codons.
Expression from all vectors was confirmed by the analysis of products obtained from in vitro transcription-translation as A capture enzyme-linked immunosorbent assay (ELISA) specific for the E2 protein was used to document the possible presence of E2 in supernatants of pCIE2t-transfected cells. This sandwich assay uses monoclonal anti-E2 antibodies directed at nonoverlapping epitopes on the E2 protein and has a sensitivity of detection of 1 ng/ml (31a). Although cell supernatants were tested at different times posttransfection, secretion of E2 was never detected (data not shown). Secretion levels of HBV-HCV-expressed fusion antigens were assessed by a commercially available capture ELISA that uses anti-HBV antibodies (MONOLISA AgHBs; Sanofi Diagnostic, Pasteur, France) and as previously described (32) . The results indicated that secretion was very low or absent, ranging from 0 to 2 ng/ml at 48 h posttransfection (data not shown).
Seroconversion. Figure 2 illustrates anti-E2 seroconversion rates observed following i.m. or i.e. immunization with the different E2-expressing plasmids. Female BALB/c mice (H2d), 6 to 8 weeks old, were purchased from Charles River (Saint Aubin-les-Elbeufs, France). All DNA preparations were generated with Qiagen purification columns (Diagen, Hilden, Germany). The pcDNA3 vector (Invitrogen) or pCI vector was typically used as a negative control in all experiments described thereafter. The i.m. injection in the tibialis anterior muscles were performed as previously described (32) . Following primary immunization with 100 g of DNA, two additional injections of the same DNA solution were given at 3-week intervals. The i.e. immunization or biolistic injection of DNA was performed with a gene gun (Accell instrument; Agracetus, Middleton, Wis.). Plasmid DNA was precipitated on gold powder (2.6-m diameter; Degussa, South Plainfield, N.J.) at a density of 5 g of DNA per mg of powder as previously described (17) . DNA-containing gold particles were injected into preshaved mouse abdominal skin at DNA-to-gold ratios resulting in the injection of 2.5 g of DNA per shot. Each animal received two deliveries per immunization. One booster injection of the same amount of DNA was performed 8 weeks after the initial injection. Blood samples were obtained by retroorbital puncture at 3-week intervals until 21 weeks postinoculation (p.i.) and stored at Ϫ20°C until examined. Anti-E2 antibodies were assayed with a highly purified vaccinia virusexpressed E2 protein derived from a subtype 1b isolate (INNO-test for anti-E2 antibodies; INNOGENETICS). The purified protein (a truncated form) encompasses amino acids (aa) 384 to 673, and its purity has been evaluated at Ͼ99.7% by silver stain analysis. Sera were typically tested at a 1:20 dilution. The tests were carried out as specified by the manufacturer except that the anti-human immunoglobulin G (IgG) conjugate was replaced by an anti-murine IgG peroxidase conjugate (Jackson) with TMB as the substrate.
Seroconversion to anti-E2 antibodies could be observed with all injected plasmids. A 100% seroconversion was attained following i.e. immunization for all constructs tested by week 18 p.i., while mice given i.m. injections displayed on average lower seroconversion rates, in some cases as low as 50%. For four plasmids, pS2.SE2B, pS2.SE2C, pS2.SE2D, and pCIE2t, 100% seroconversion was observed as early as week 6 following i.e. immunization. In all cases, the rates stayed stable in all groups of animals throughout the whole study.
Antibody titers and isotypes. Table 1 summarizes maximal and mean antibody titers obtained at three different times (weeks 6, 12, and 18) following i.m. or i.e. immunization, as well as isotypes of induced antibodies. E2 antibody titers were calculated as the serial threefold dilution which gave an optical density (OD) cutoff. The cutoff was established as the mean OD ϩ 3 standard deviations for 10 serum samples obtained from control mice. For the determination of E2 antibody isotypes in murine sera, specific goat anti-murine IgG1, IgG2a, IgG2b, IgG3, and IgM antibodies (Pharmingen) were coated onto Nunc Maxisorb microplates for 1 h at 37°C at 5 g/ml. The plates were blocked overnight at 4°C with phosphatebuffered saline-0.1% casein. A 1:40 dilution of the sera in block buffer was incubated for 1 h at 37°C and then further incubated with streptavidin-peroxidase conjugate for 30 min at 37°C (Jackson). TMB substrate was added and left to react for 20 min at 37°C. The reaction was stopped by the addition of 0.1 N HCl, and the OD was read at 450 nm. Statistical analysis was performed by the Mann-Whitney test. Titers for each plasmid and each injection mode were compared at each individual time point (6, 12 , and 18 weeks). Thus, a total of three sets of data points were analyzed for each plasmid.
For all injected plasmids, the highest anti-E2 antibody titers were obtained following i.e. immunization. The most immunogenic protein appeared to be encoded by the pCIE2t plasmid. For this plasmid, either mode of immunization induced titers that reached Ͼ1:43,700. Proteins encoded by the pS2.SE2A and pS2.SE2C plasmids were also good immunogens, inducing antibody titers up to 1:12,946 and Ͼ1:43,700, respectively, fol-
FIG. 1. Expression vectors. (A)
A construct, pCIE2t, expressing 334 aa of the HCV E2 (C-truncated E2), was derived by inserting the HCV sequence directly after the T7 promoter of the pCI vector from Promega. (B) Five partial E2-derived sequences (E2A to E2E) were inserted in the pre-S2 sequence of the HBsAg from the pCMVS2.S vector as a replacement for the EcoRI-XhoI insert. The resulting expression vectors were pS2.SE2A, pS2.SE2B, pS2.SE2C, pS2.SE2D, and pS2.SE2E. These HBV-HCV chimeric vectors express fusion proteins carrying both HCV-E2 and HBsAg determinants. (C) Schematic representation of the hydrophilicity plot and antigenic indexes deduced for insert A to E sequences, according to computer predictions (Kyte-Doolittle and Jameson-Wolf). CMV, cytomegalovirus. lowing i.e. immunization. The three other HBV-HCV fusion proteins encoded by plasmids pS2.SE2B, pS2.SE2D, and pS2.SE2E induced, independent of the immunization mode, very low antibody titers, in all cases Ͻ1:240. A striking difference between the two immunization modes was observed for plasmid pS2.SE2C. At 12 weeks p.i., while i.m. immunization resulted in a maximal titer of only 1:300 (mean, 1:170), anti-E2 antibody titers up to 1:43,700 (mean, 1:15,134) could be measured following i.e. immunization. Although the number of animals included in each group was rather small (n ϭ 4), this difference was statistically significant (P ϭ 0.02). The difference in antibody titers induced following i.m. or i.e. immunization was also statistically significant for plasmids pS2.SE2D and pCIE2t (P ϭ 0.02 to 0.04). Overall, there was no difference in the isotypes of induced antibodies between the two modes of injection; they were IgG2a and IgG2b. IgG1 was never detected in this study.
Under the experimental conditions used in our study, in addition to inducing higher antibody titers in comparison with i.m. immunization, i.e. immunization appeared to induce longer-lasting or increasing titers while i.m. injection induced titers that tended to either become stable or decrease within the 18-week period of follow-up of the study. A longer period of analysis is nonetheless warranted to further confirm such observation.
Characterization of recognized determinants: preliminary mapping and identification of subtype variable or conserved domains. (i) IF studies. Studies were performed to further characterize the determinants recognized by the polyclonal antibodies induced following injection of pCIE2t. Transienttransfection experiments were performed essentially as previously described (32) with the HBV-HCV chimeric vectors pS2S.E2A to pS2S.E2E followed by IF studies. Sera from mice immunized with pCIE2t, either i.m. or i.e., were capable of recognizing all fusion proteins, suggesting that antibodies induced by this vector are directed at a wide range of determinants mapping in different domains of E2.
(ii) Western blot analysis. The specificity of the induced anti-E2 antibodies was evaluated by immunoblotting with protein preparations containing a subtype 1a or subtype 1b E2 protein (Fig. 3) . Baculovirus-expressed E2 proteins truncated from the hydrophobic C-terminal end, from a genotype 1a isolate and a genotype 1b isolate, were used either as highly purified proteins (for E2 1b; generous gift from H. Jacobsen) or as supernatants from cultures (for E2 1a; generous gift from G. Baccala). Protein preparations were analyzed by immunoblotting after separation by electrophoresis on sodium dodecyl sulfate (SDS)-10% polyacrylamide gels. For one given plasmid, sera (1:50 dilution) obtained from either i.m.-or i.e.-immunized mice at 15 weeks p.i. were pooled and incubated at 4°C overnight as described previously (32) . Signals were then revealed by using the enhanced chemiluminescence (ECL) blotting analysis system (Amersham, Arlington Heights, Ill.). As a positive control, sera (dilution 1:50) from patients infected with a HCV subtype 1a or 1b were used.
Use of an HCV-positive human serum (infected with a sub- type 1a isolate) revealed for both antigen preparations a band of 55 kDa, corresponding to the expected glycosylated form of truncated E2 (far right lane). In the highly purified preparation of E2 1b, a 112-kDa product could also be detected, it probably corresponded to (covalently linked) dimers of the antigen generated during the purification process. A nonspecific band of approximately 84 kDa could sometimes be detected in the E2 1a preparation. Sera from mice given injections of the pcDNA3 plasmid were used as controls. All sera generated by i.m. injection, except from mice given the pS2.SE2D plasmid, reacted with the subtype 1a 55-kDa protein (top left panel), while sera generated by i.e. immunization resulted in detectable signals for plasmids pS2.SE2C and pCIE2t only (top right panel). Following i.m. immunization, reactivity against the subtype 1b protein (both the 55-and 112-kDa forms) was detected only with sera obtained from animals given injections of the pS2.SE2A, pS2.SE2E, and pCIE2t plasmids (bottom left panel), while detectable signals with sera obtained from i.e.-injected animals could be observed for the pS2.SE2C, pS2.SE2D, and pCIE2t plasmids (a very weak reactivity could also be seen for pS2.SE2A-and pS2.SE2B-induced antibodies). Most striking was the lack of (cross-)reactivity of sera from mice immunized i.m. with the pS2.SE2C plasmid against the subtype 1b E2 antigen in spite of a strong signal observed against the subtype 1a protein. This was in sharp contrast to the observation made with i.e.-induced sera. Also unexpected was the lack Similar observations could be made for the pS2S.E2E plasmid in spite of very low antibody titers generated by either injection mode for this plasmid (Table 1) . (iii) ELISA. As Western blot analysis were performed under denaturing conditions, it could be speculated that the observed immunoreactivity was probably targeted at linear determinants. A panoply of synthetic peptides (25 to 30 aa in length), mapping within the E2A, E2C, and E2E inserts and derived from the subtype 1a (n ϭ 5) or 1b (n ϭ 5) E2 sequences used for baculovirus expression of the antigen, was used in ELISA to further characterize the immunoreactivity of the induced sera. For each group of mice, sera were either pooled prior to being tested (from week 21 or 24 p.i.) or assayed as individual serum samples by selecting the highest-titer serum sample from each group of mice. The experimental conditions were as described by Mink et al. (37) . All sera were tested at a 1:100 dilution. Only sera giving absorbance values more than 3.0 times the absorbance value of negative sera were considered positive.
Sera from mice immunized i.m. or i.e. with pS2.SE2A, pS2.SE2C, pS2.SE2E, and pCIE2t were tested. Only four peptides were reactive, as indicated in Fig. 4 : A2a and A2b derived from the subtype 1a (A2a) and 1b (A2b) E2 sequence, respectively, and mapping within insert E2A (aa 411 to 437), and Ca and Cb derived from the subtype 1a (Ca) and 1b (Cb) E2 sequence, respectively, and mapping within insert E2C (aa 493 to 576). As shown in Fig. 4 , both the Ca-and Cb-derived peptides were recognized by i.e.-induced sera obtained from pS2.SE2C-as well as pCIE2t-injected mice, while only the subtype 1a peptide, Ca, could be recognized by i.m.-induced sera for either plasmids. On the other hand, none of the Aderived peptides were recognized by antibodies following i.e. immunization with either the pS2S.E2A or pCIE2t plasmids, while they were recognized by i.m.-induced sera from pCIE2t injected mice (under the experimental conditions used, no reactivity could be observed with sera from pS2.SE2A i.m.-injected mice). These observations further document the differential immune reactivity of induced antibodies observed by Western blot analysis. In addition, they illustrate that sera from mice given injections of the near-full-length E2-expressing plasmid, pCIE2t, display an equivalent immune reactivity to those obtained with plasmids carrying restricted E2 determinants.
While the overall data indicate that both immunization modes can induce cross-reactive antibodies capable of recognizing subtype 1a and 1b determinants, such reactivity appears to depend on both the type of antigen expressed and the delivery mode implemented.
Immunoprecipitation studies of heterodimer E2 proteins. HCV E2 protein has been reported to interact with E1 to form E1E2 heterodimer complexes that exist as two different forms: noncovalently associated heterodimers and larger complexes stabilized by intermolecular disulfide bonds (9, 17) . The noncovalently associated E1E2 heterodimers are thought to be the functional subunits incorporated in the virion particles, although direct observations of infectious virions have yet to be made. Sera from plasmid-immunized mice were used to immunoprecipitate the E2 protein as well as E1E2 noncovalently linked complexes. Successful precipitation of such complexes would be an indication of the capacity of the generated antibodies to recognize the expected functional form of the protein and thus of their potential to be neutralizing.
HepG2 cells were coinfected with vTF7-3, a vaccinia virus recombinant expressing the T7 DNA-dependent RNA polymerase (14) , together with the vaccinia virus-HCV recombinants vHCV170-809, expressing truncated forms of the HCV-H polyprotein from amino acids 170 to 809 (13) . HepG2 cells were infected at a multiplicity of infection of 10 PFU per cell as described previously (9) . Between 2 and 6 h postinfec- tion, cells were metabolically labeled with 35 S translabel (ICN; 50 mCi/ml). Labeled infected cells were then lysed with 0.5% Nonidet P-40 in 10 mM Tris-HCl (pH 7.5)-150 mM NaCl-2 mM EDTA, and immunoprecipitations were carried out as described previously (10) . Figure 5A shows immunoprecipitation products from cell extracts containing [
35 S]methionine-labeled E1 and E2 proteins with sera from pS2S.E2A pS2S.E2E (lanes A to E), pCIE2t, or pcDNA3 i.m.-injected mice under reducing conditions. For each plasmid, sera obtained at 15 weeks p.i. from the different mice were pooled for the assay. By using E1E2-containing extracts, a specific signal for both proteins could be detected above background with sera from pS2.SE2A-, pS2.SE2C-, pS2.SE2E-, and pCIE2t-injected mice. Absent or weak precipitation of E2 by sera E2B and E2D could be due to the low antibody titers characterizing these sera (Table 1) . Alternatively, it could suggest that all or most of the epitopes recognized by these sera are probably buried in the structure of the full-length E2 protein. The four sera that coprecipitated E1 indicate that the corresponding plasmid vectors are capable, upon injection, of inducing antibodies recognizing E1E2 complexes. In addition, immunoprecipitation of these complexes under nonreducing conditions was performed with all sera. Only sera from pCIE2t-injected mice were able to coprecipitate noncovalently linked E1 (Fig. 5B) . Those data suggest that such sera can recognize the noncovalently linked mature heterodimer. For all experiments described above, identical results were obtained with sera from i.e.-immunized mice for all plasmids.
Conclusions. The first DNA immunization experiment in mouse muscle was reported by Wolf et al. in 1990 (51) . Since then, major histocompatibility complex MHC class II-mediated antigen presentation for elicitation of antibody responses following DNA immunization in mice or in nonhuman primates has been reported for a number of viral genes, in particular viral glycoproteins and viral envelope protein genes, including the human immunodeficiency virus gp120, the simian immunodeficiency virus gp 130/35, the HBsAg, and the rabies virus glycoprotein (6, 15, 31, 37, 47, 48, 52) . All these studies have described responses obtained following injection of plasmids expressing full-length proteins. In this study, we have diversified the mode of immunization and the number of immunogenic domains of the HCV glycoprotein E2 that could be exploited in nucleic acid-based experiments. The purpose was to evaluate the performance of this new mode of vaccination applied to HCV envelope proteins, specifically E2, as well as to gain insights into the immunogenic nature of E2. DNA immunization with HCV genes has so far been described only in studies focused on the viral nucleocapsid (28, 32, 45) .
We were able to document efficient induction of anti-E2 antibodies following direct DNA injection. More specifically, we could identify three restricted immunogenic domains mapping within inserts E2A (aa 384 to 443), E2C (aa 504 to 554) and E2E (aa 609 to 674). Except for the HVR from which immunogenic peptides have been derived and evaluated in mice (40) , no studies have yet described the potential immunogenicity of restricted domains of HCV E2. The use of HBV-HCV chimeric plasmids allowed us to direct immune responses at restricted determinants. This may be relevant for vaccine development, as epitopes important for control of HCV infection will be identified and/or to possibly avoid the induction of facilitating antibodies (25) . Because of a lack of appropriate analytical tools, such as an efficient in vitro replication assay and of a convenient animal model besides the chimpanzee, it is particularly difficult to evaluate the relevance of immune responses generated by any vaccine approach targeted at HCV. Although we could not study the neutralizing capacity of anti-E2 antibodies generated by the various DNA plasmids used in our study, we could nonetheless provide informative data about the potential for cross-reactivity of the induced antibodies by using two different subtype-derived antigens, a subtype 1a antigen and a subtype 1b E2 antigen. These two subtypes of HCV are among the most prevalent worldwide. We showed that DNA injection of E2-encoding plasmids can induce crossreactive antibodies. Nonetheless, immunoreactivity of the induced antibodies appeared to be linked both to the type of antigen expressed and to the delivery mode.
Delivery of DNA to the epidermis rather than to muscles has been shown to be, as we observed in our study, more effective at inducing higher antibody titers (16, 18, 48) . It should be noted, nonetheless, that different immunization schedules were used in our study for i.m. and i.e. delivery of the plasmids. In particular, boosts given i.m. could have been too close to each other and may have had a depressing effect on the immune responses induced. Studies are under way in our laboratory to address this issue. For the influenza model, Pertner et al. have shown in a recent study that these two modes of injection, while inducing similar CTL responses, could induce different levels of IgG-specific antibodies as well as different cytokine profiles (38) . No study has yet addressed the question whether these two modes of injection could influence the recognition of determinants within one given antigen and/or the efficiency of induced antibodies to cross-react against different subtype-derived antigens. Our data indicate that at least in the HCV E2 model, a different spectrum of immunogenic sequences appears to be exploited by the host and/or exploited at different degrees, in part dependent on the injection mode. Whether differences in the processing of the expressed antigen, in the amount of expressed antigens, or in the presentation of the determinant(s) to the immune system may account for the differences observed remains to be determined. For example, expression of injected plasmids probably takes place in different types of cells, and processing of the expressed antigens could consequently be different. In addition, different antigenpresenting cells (APCs) may be recruited depending on the immunization mode. To date, very few studies have addressed Immunoprecipitations were performed under reducing (R) and nonreducing (NR) conditions with sera from pCIE2t-injected mice. The results are shown for i.m.-generated sera. Experimental conditions were essentially as described previously (9) . The immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis (10% acrylamide). Expected signals for the E1 and E2 proteins and protein molecular mass markers are indicated on the figure. the nature of the APCs recruited following immunization with plasmid DNA. A recent study by Doe et al. suggested that professional APCs of hematopoietic origin indeed appear to be involved in the induction of immune responses following i.m. injection (8) . As for i.e. injection of particles, the epidermis is particularly rich in epidermal Langerhans cells (up to 4%). These cells are presumably important players in antigen presentation (2) and are probably involved in the mechanisms responsible for the observed induced immune response that are linked to this immunization mode. One factor that may also influence the induction of antibodies could be the genetic background of the mice. It has been shown, for example, that mouse haplotypes could affect seroconversion rates and possibly antibody titers following injection of HCV nucleocapsidencoding plasmids (21) .
We showed that DNA-generated antibodies could immunoprecipitate noncovalent E1E2 complexes. Such complexes are thought to exist on the surface of virions (9) . A logical speculation would be that some of the antibodies capable of recognizing such structures may be neutralizing. In our study, antibodies induced by the near-full-length E2-containing plasmid displayed this property. Rosa et al., using a highly purified subtype 1a E2 protein, found that the human antibodies capable of neutralizing the binding of E2 to specific cell lines were present in more than 40% of HCV chronic carriers (40) . Exploitation of the system of Rosa et al. may be relevant to further characterize our induced anti-E2 antibodies, although this assay cannot test for direct neutralization.
DNA vaccines have been shown to be potent inducers of neutralizing antibodies (37, 48, 52) , in particular when the plasmids are injected via gene gun delivery (17) . In the case of HCV, it remains to be seen whether nucleic acid-based immunization could result in the induction of such antibodies in a susceptible animal model.
